Clifford Chance advises the underwriters on ONWARD Medical’s €40 million capital increase

Global law firm Clifford Chance has advised the underwriters on ONWARD Medical NV’s approximately €40 million capital increase, by way of a bookbuild offering through a private placement with institutional investors.

ONWARD Medical is a leading neurotechnology company developing therapies to restore movement, function and independence in people with spinal cord injuries (SCI) and other movement disabilities.

Settlement of the shares and their admission to listing and trading on Euronext Brussels, Euronext Amsterdam and Euronext Paris took place on 20 April 2026. Read more about this transaction here.

Stifel acted as sole global coordinator and, together with Degroof Petercam, as joint bookrunners of the private placement.

This transaction follows ONWARD Medical's €50 million capital increase in 2025, on which Clifford Chance previously advised.

The Clifford Chance cross-border team was led by Olivier Plessis and Han Teerink, with support from Robert Bulte.